The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of TherapeuticsMD, Inc. (NYSEMKT: TXMD) who purchased shares between July 7, 2016 and May 7, 2017. The action, which was filed in the USDC for the Southern District of Florida, alleges that the Company violated federal securities laws.
In particular, the complaint alleges that (i) the Company’s New Drug Application (NDA) submission for TX-004HR was deficient; (ii) the Company’s NDA submission for TX-004HR was not supported by the complete TX-004HR clinical program and/or the clinical program was deficient; (iii) the Company’s deficient NDA would likely cause a delay of the FDA’s potential approval of the TX-004HR NDA.
Shareholders have until June 19, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
Please fill out the form to learn more